source
- Biohaven could get up to $795M in epilepsy alliance with SK BioAt the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.BioSpace · 4h ago↗ source
- J&J’s Imaavy gains first-in-class label for warm autoimmune hemolytic anemiaJ&J announced that its monoclonal antibody Imaavy has received a label expansion in the United States. The expanded indication makes Imaavy the first therapy approved specifically for warm autoimm…